Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Innate Immunotherapeutics completes $A10mm initial public offering

Executive Summary

Innate Immunotherapeutics Ltd. (immunomodulators for autoimmune diseases and potentially cancer) raised $A10mm ($6.5mm) through its initial public offering. The company sold 50k shares at $A0.20 to existing international buyers and new Australian institutional investors. The Australian Ethical Smaller Companies Trust provided at least $A3mm.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
    • Vaccines
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies